What the Study Found (In Plain English)
Published in Vaccine (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: Despite the availability of enterovirus type 71 (EV71) vaccines, evidence on long-term protection remains limited. Key clinical takeaway: Under the current EV71 epidemic conditions in China, the two-dose regimen of the inactivated EV71 vaccine provides durable protection exceeding 72% for at least 20 years.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Vaccine, 2026-03-19; Phase III Randomized Trial; Rigor 88/100): Under the current EV71 epidemic conditions in China, the two-dose regimen of the inactivated EV71 vaccine provides durable protection exceeding 72% for at least 20 years.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.